Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 1728 for:    psoriasis

Genetic Analysis of Pediatric Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03768284
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : December 7, 2018
Sponsor:
Collaborators:
National Psoriasis Foundation
Icahn School of Medicine at Mount Sinai
Information provided by (Responsible Party):
Amy Paller, Northwestern University

Brief Summary:
This study will ascertain approximately 150 subjects, which will include pediatric psoriasis patients diagnosed before age 12, parents not affected by psoriasis, and if a family history is indicated, up to third-degree family members. Saliva (or buccal swabs in the case of infants) will be obtained for DNA isolation.

Condition or disease Intervention/treatment
Psoriasis Other: Saliva or buccal sample

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Genetic Analysis of Pediatric Psoriasis
Actual Study Start Date : October 17, 2018
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : October 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Psoriasis patients
Patients (of any age) who developed psoriasis before 12 years of age and who have no family history of psoriasis in either parent.
Other: Saliva or buccal sample
Saliva or buccal sample

Parents of psoriasis patients
Parents of patients who developed psoriasis before 12 years of age
Other: Saliva or buccal sample
Saliva or buccal sample

Up to third-degree family members with or without psoriasis
Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.
Other: Saliva or buccal sample
Saliva or buccal sample




Primary Outcome Measures :
  1. CARD14 mutations [ Time Frame: one year ]
    The number of pathogenic mutations identified in CARD14 in a pediatric psoriasis cohort


Secondary Outcome Measures :
  1. De novo mutations [ Time Frame: one year ]
    The number of candidate psoriasis genes through the identification of de novo mutations in moderate-to-severe pediatric cases who require systemic intervention.


Biospecimen Retention:   Samples With DNA
Saliva (or buccal swabs in the case of infants) will be obtained for DNA isolation.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study will ascertain approximately 150 subjects, which will include pediatric psoriasis patients diagnosed before age 12, parents not affected by psoriasis, and if a family history is indicated, up to third-degree family members.
Criteria

Inclusion Criteria:

  • Patients (of any age) who developed psoriasis before 12 years of age and who have no family history of psoriasis in either parent.
  • Parents of patients who developed psoriasis before 12 years of age
  • Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.

Exclusion Criteria:

  • Patients, parents, and other family member unable to give a saliva or buccal swab sample.
  • Patients, parents, and other family member unable to give written informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03768284


Contacts
Layout table for location contacts
Contact: Dermatology CTU 312-503-5944 NUderm-research@northwestern.edu

Locations
Layout table for location information
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago Recruiting
Chicago, Illinois, United States, 60611
Contact: DermatologyCTU    312-503-5944    NUderm-research@northwestern.edu   
Principal Investigator: Amy Paller, MD         
Sponsors and Collaborators
Northwestern University
National Psoriasis Foundation
Icahn School of Medicine at Mount Sinai
Investigators
Layout table for investigator information
Principal Investigator: Amy Paller, MD Northwestern University

Layout table for additonal information
Responsible Party: Amy Paller, Principal Investigator, Northwestern University
ClinicalTrials.gov Identifier: NCT03768284     History of Changes
Other Study ID Numbers: 2018-2259
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: December 7, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases